- Report
- March 2025
- 194 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- March 2025
- 181 Pages
Global
From €5181EUR$5,450USD£4,353GBP
- Report
- March 2025
- 182 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- March 2025
- 200 Pages
Global
From €4268EUR$4,490USD£3,586GBP
- Report
- August 2024
- 140 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- May 2024
- 128 Pages
Global
From €6178EUR$6,499USD£5,190GBP
- Clinical Trials
- December 2024
- 180 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- June 2024
- 198 Pages
Global
From €7558EUR$7,950USD£6,349GBP
- Report
- October 2024
- 250 Pages
Global
From €4705EUR$4,949USD£3,952GBP
- Report
- May 2024
- 224 Pages
Global
From €4749EUR$4,995USD£3,989GBP
- Report
- August 2024
- 52 Pages
Global
€16304EUR$17,150USD£13,697GBP
- Report
- March 2025
- 192 Pages
Global
From €4706EUR$4,950USD£3,953GBP
- Report
- February 2025
- 383 Pages
Global
From €5181EUR$5,450USD£4,353GBP
- Report
- July 2024
- 135 Pages
Global
From €2851EUR$2,999USD£2,395GBP
- Report
- December 2024
- 99 Pages
Global
From €3755EUR$3,950USD£3,155GBP
- Report
- July 2024
- 100 Pages
Global
From €3565EUR$3,750USD£2,995GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1188EUR$1,250USD£998GBP
- Report
- June 2024
- 80 Pages
United States
From €3755EUR$3,950USD£3,155GBP
- Report
- June 2024
- 140 Pages
Latin America
From €3678EUR$3,869USD£3,090GBP
- Report
- June 2024
- 120 Pages
North America
From €3678EUR$3,869USD£3,090GBP

The Sickle Cell Drug market is a subset of the larger Hematological Drugs market. It is composed of drugs used to treat sickle cell disease, a genetic disorder that affects red blood cells. These drugs are used to reduce the frequency of painful episodes, reduce the risk of organ damage, and improve the quality of life for those affected. Common treatments include hydroxyurea, which helps to reduce the number of sickle cells in the blood, and L-glutamine, which helps to reduce the risk of organ damage. Other treatments include blood transfusions, stem cell transplants, and gene therapy.
Companies in the Sickle Cell Drug market include Novartis, GlaxoSmithKline, Pfizer, Sanofi, and Merck. Show Less Read more